Holland Capital Announces Successful Exit of Defibrion to IK Partners
Amsterdam/Groningen, 23 July 2024 – Holland Capital is proud to announce that IK Partners (IK) has signed an agreement to acquire our portfolio company, Defibrion. Since 2019, Defibrion’s management team has successfully collaborated with Holland Capital. The shares of Defibrion are being sold to IK and the company’s management team. IK is a leading European private equity firm focused on investments in the Benelux, DACH, France, Nordics and the UK.
Defibrion: A Leading Provider in AED Distribution and Safety Products
Founded in 2008 by the current CEO Joshua Valkenier and based in Groningen, Defibrion is a market leader in the distribution of automated external defibrillators (AEDs) and related safety products. The company offers a wide range of products and services aimed at enhancing workplace safety. With over 6,400 customers worldwide, Defibrion serves as a one-stop-shop for emergency response needs. Its customer base, which includes more than 900 resellers in Europe and North America, comprises various end users such as offices, sports clubs, and government institutions.
Strategic Growth and Expansion
Since 2019, Holland Capital has been involved with Defibrion as a shareholder. They actively supported the management in professionalizing the organization and the strategic development of the company. Through a successful buy-and-build strategy and a focus on geographical expansion in Western Europe, Defibrion has been able to grow successfully.
Defibrion is now on the brink of a new phase in its development, which will be supported by IK. In this new phase, Defibrion will further scale up its existing operations, broaden its offerings, and expand into new markets. The strategic plan also includes exploring further buy-and-build opportunities to promote consolidation in the fragmented market of AEDs and related safety products.
Joshua Valkenier, founder and CEO of Defibrion, said: “When Holland Capital joined Defibrion as a shareholder in 2019, we had the ambition to internationalize, professionalize, and further expand our organization. I am pleased that we have achieved this and am grateful to Holland Capital for the pleasant and successful collaboration.”
Ewout Prins, managing partner of Holland Capital, commented: “The collaboration with Joshua Valkenier and the Defibrion team was both successful and enjoyable. When we joined, we were convinced that the AED market offered interesting growth opportunities, and Defibrion has demonstrated this. Their dedication and vision have played a crucial role in achieving this growth. We are proud to have contributed to the successful growth of Defibrion and its life-saving products. We wish the team much success in this next phase of growth.”
About Holland Capital
Holland Capital has been responsibly and successfully investing in promising Dutch and German SMEs with growth ambitions for over 40 years. The team understands entrepreneurship and strives for an open, sustainable, and professional relationship with the management teams of the companies they invest in, with the common goal of realizing growth. Holland Capital has offices in Amsterdam and Düsseldorf. With specialized sector teams, it focuses on the Healthcare, Technology, and Agrifood-Tech sectors. They understand the dynamics and opportunities, and have an extensive network in these sectors.
Quantib presents revolutionary software for dementia and MS diagnosis support and tracking
Rotterdam, The Netherlands – August 1st 2018. Quantib, market leader in artificial intelligence tools for radiology, released a major upgrade of their dementia and MS diagnosis support software Quantib™ ND. A substantial list of new features supporting the diagnosis...
Quantib presenteert revolutionaire software voor ondersteuning en tracking van dementie en MS-diagnose
Rotterdam, Nederland, 1 augustus 2018 - Quantib, marktleider in hulpmiddelen voor kunstmatige intelligentie voor radiologie, heeft een belangrijke upgrade van hun dementie en MS-diagnose-ondersteuningssoftware Quantib ™ ND uitgebracht. Een substantiële lijst met...
MedAngel takes away doubts about the effectiveness of medication
Digital healthcare startup receives investment from Holland Venture and Oost NLApeldoorn/Amsterdam, 13th of July 2018 – Uncertainties regarding the effectiveness of injectable medications is a major concern for millions of patients. There are many factors that can...
MedAngel neemt twijfels over werkzaamheid medicatie weg
Digitale healthcare start-up ontvangt investering van Holland Venture en Oost NL Apeldoorn/Amsterdam, 13 juli 2018 - Onzekerheid over de werking van je medicijnen, geen controle hebben over hoe je dag loopt, het houdt veel chronisch zieke patiënten bezig. Er zijn...
Avensus Group expands its security activitities by acquiring auditconnect
Amsterdam, 6th of July 2018 – Avensus Group acquires AuditConnect at the beginning of July 2018. The company focusses, with audit- and consultancy-activities, on improving the security- and IT-processes at large and medium-sized companies. The acquisition fits...
Avensus groep zet volgende stap in buy-and-build strategie met overname auditconnect
Amsterdam, 6 juli 2018 – Avensus Groep neemt vanaf begin juli 2018 AuditConnect over. De onderneming richt zich met audit- en consultancy-activiteiten op het verbeteren van de security- en IT-processen bij grote en middelgrote organisaties. Deze overname past...
Amsterdam
Krijn Taconiskade 426
1087 HW Amsterdam
+31 (0) 20 3119411
Düsseldorf
Königsallee 42
40212 Düsseldorf
+49 (0) 211 96290120
Contact
info@hollandcapital.nl